Hakutulokset - Kevin M. Chin

  • Näytetään 1 - 13 yhteensä 13 tuloksesta
Tarkenna hakua
  1. 1
    Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

    Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma Tekijä Ilyssa O. Gordon, Takisha Wade, Kevin M. Chin, Jerome I. Dickstein, Thomas F. Gajewski

    Julkaistu 2008
    Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

    Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy Tekijä Axel Hoos, Ramy Ibrahim, Alan J. Korman, Kald Abdallah, David M. Berman, Vafa Shahabi, Kevin M. Chin, Renzo Canetta, Rachel Humphrey

    Julkaistu 2010
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

    Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials Tekijä Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Kevin M. Chin, L. Cykowski, Veerle de Pril, Rachel Humphrey, Célèste Lebbé

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Tekijä Susan F. Slovin, Celestia S. Higano, Omid Hamid, Sheela Tejwani, Andrea Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry, Tomasz M. Beer

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

    Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial Tekijä Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun‐Wook Lee, Vijay Kasturi, Kevin M. Chin, Anja von Heydebreck, James L. Gulley

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b... Tekijä James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, H. Grote, Anja von Heydebreck, Kevin M. Chin, Jean-Marie Cuillerot, Karen Kelly

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study Tekijä Vivek Naranbhai, Mathias Viard, Michael Dean, Stefan Groha, David A. Braun, Chris Labaki, Sachet A. Shukla, Yuko Yuki, Parantu K. Shah, Kevin M. Chin, Megan Wind‐Rotolo, Xinmeng Jasmine Mu, Paul B. Robbins, Alexander Gusev, Toni K. Choueiri, James L. Gulley, Mary Carrington

    Julkaistu 2021
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Tekijä Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Tekijä Luc Dirix, István Takács, Guy Jérusalem, Petros Nikolinakos, Hendrik‐Tobias Arkenau, Andres Forero‐Torres, Ralph V. Boccia, Marc E. Lippman, Robert A. Somer, Martin Šmakal, Leisha A. Emens, Borys Hrinczenko, W. Jeff Edenfield, Jayne S. Gurtler, Anja von Heydebreck, H. Grote, Kevin M. Chin, Erika Hamilton

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

    Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Tekijä Raffit Hassan, Anish Thomas, John Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin L. Chen, Jean‐Pierre Delord, Afshin Dowlati, Samith T. Kochuparambil, Matthew H. Taylor, John D. Powderly, Ulka N. Vaishampayan, Claire F. Verschraegen, H. Grote, Anja von Heydebreck, Kevin M. Chin, James L. Gulley

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Tekijä Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Gerald P. Linette, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Kevin M. Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

    Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial Tekijä Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan, Lisa M. Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L. Marté, Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin M. Chin, Jeffrey Schlom, James L. Gulley

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

    Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma Tekijä Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Éva Szabó, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin M. Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: